Advertisement

Motor Neurone Disease: Experience with Large Multicentre Trials

  • T. J. Steiner
Chapter

Abstract

All multicentre trials are challenging, whatever the disease under study. Motor neurone disease (MND; USA: amyotrophic lateral sclerosis, ALS) brings to the challenge a particular set of difficulties. Here is a condition that exists in different forms and presents extremely variably. It has its onset in a wide age range with, accordingly, a range of concomitant illnesses, progresses inexorably but somewhat unpredictably and again very variably, and offers no obvious manner of measurement. In pathophysiological terms, reversal of the condition is unattainable, arrest is the Holy Grail and slowed rate of progression the most realistic outcome to hope for. In other words, patients at the conclusion of a trial will be worse off than at entry.

Keywords

Amyotrophic Lateral Sclerosis Force Vital Capacity Motor Neurone Disease Sickness Impact Profile Large Multicentre Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutic trials. J Chron Dis 1967; 20: 637–648.PubMedCrossRefGoogle Scholar
  2. 2.
    Guiloff RJ, Goonetilleke A, Emami J. Riluzole and amyotrophic lateral sclerosis. Lancet 1996; 348: 336–337.PubMedCrossRefGoogle Scholar
  3. 3.
    Anon. Riluzole for amyotrophic lateral sclerosis [editorial]. Drugs Ther Bull 1997; 35: 11–12.CrossRefGoogle Scholar
  4. 4.
    Brooke AS, Steiner TJ. Special problems of physiotherapy trials in motor neuron disease. In: Clifford Rose F, editor. Amyotrophic lateral sclerosis. New York: Demos, 1990:181193.Google Scholar
  5. 5.
    Robinson I. Ethical issues and methodological problems in the conduct of clinical trials in amyotrophic lateral sclerosis. In: Clifford Rose F, editor. Amyotrophic lateral sclerosis. New York: Demos, 1990: 195–213.Google Scholar
  6. 6.
    Munsat TL, Brooks BR. Don’t throw the baby out with the bathwater [letter]. Neurology 1987; 37: 544–545.PubMedCrossRefGoogle Scholar
  7. 7.
    Chaturvedi S. Clinical trials and financial reimbursement [letter]. Stroke 1998; 29: 1256.PubMedCrossRefGoogle Scholar
  8. 8.
    Steiner TJ. Branched-chain amino-acids in ALS: the European trial. In: Clifford Rose F, editor. New Evidence in MND/ALS Research. London: Smith-Gordon, 1991: 315–316.Google Scholar
  9. 9.
    Plaitakis A, Smith J, Mandeli J, Yahr MD. Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis. Lancet 1988; I: 1015–1018.PubMedCrossRefGoogle Scholar
  10. 10.
    The Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure. Neurology 1993; 43: 2466–2470.CrossRefGoogle Scholar
  11. 11.
    Breteler MMB. Selegiline, or the problem of early termination of clinical trials [editorial]. BMJ 1998; 316: 1182–1183.PubMedCrossRefGoogle Scholar
  12. 12.
    Barnett HJM, Sackett DL. Monitoring clinical trials [editorial]. Neurology 1993; 43: 2437–2438.PubMedCrossRefGoogle Scholar
  13. 13.
    Josefson D. Breast cancer trial stopped early [news item, with commentary: British researchers say that American trial was stopped prematurely]. BMJ 1998; 316: 1187.Google Scholar
  14. 14.
    Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. For the Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425–1431.PubMedGoogle Scholar
  15. 15.
    Bensimon G, Lacomblez L, Meininger V. ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994; 330: 585–591.PubMedCrossRefGoogle Scholar
  16. 16.
    Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994; 124 (Suppl): 96–107.PubMedCrossRefGoogle Scholar
  17. 17.
    Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, et al. and the North American ALS/IGF-I Study Group. Effect of recombinant human insulin-like growth factor-I on progression of ALS. a placebo-controlled study. Neurology 1997; 49: 1621–1630.PubMedCrossRefGoogle Scholar
  18. 18.
    Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis. description and preliminary experience. Ann Neurol; 22: 328–333.Google Scholar
  19. 19.
    Bergner M, Bobbit RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787–805.PubMedCrossRefGoogle Scholar
  20. 20.
    Mitsumoto H, Hanson MR, Chad DA. Amyotrophic lateral sclerosis: recent advances in pathogenesis and clinical trials. Arch Neurol 1988; 45: 189–202.PubMedCrossRefGoogle Scholar
  21. 21.
    Li TM, Swash M, Alberman E, Day SJ. Diagnosis of motor neuron disease in three countries. J Neurol Neurosurg Psychiatry 1991; 54: 980–983.PubMedCrossRefGoogle Scholar
  22. 22.
    Kuether G, Struppler A, Lipinski HG. Therapeutic trials in ALS: the design of a protocol. In: Cosi V, Kato AC, Parlette W, Pinelli P, Poloni M, editors. Amyotrophic Lateral Sclerosis. New York: Plenum Press, 1986: 265–276.Google Scholar
  23. 23.
    Swash M, Leigh N. Criteria for diagnosis of familial amyotrophic lateral sclerosis [Workshop report]. Neuromusc Disord 1992; 2: 7–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Munsat TL, Andres P, Taft J. The nature of clinical change in amyotrophic lateral sclerosis. In: Tsubaki T, Yase Y, editors. Amyotrophic lateral sclerosis: recent advances in research and treatment. Amsterdam: Excerpta Medica, 1988: 203–206.Google Scholar
  25. 25.
    Andres PL, Hedlund W, Finison L, Conlon T, Felmus M, Munsat 36. TL. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 1986; 36: 937–941. 37.Google Scholar
  26. 26.
    Gorringe JAL. Initial preparation for clinical trials. In: Harris EL, Fitzgerald JD, editors. The principles and practice of clinical trials. Edinburgh: Livingstone, 1970: 4146. 38.Google Scholar
  27. 27.
    Glasberg MR. Selection of patients in therapeutic trials. In: Clifford Rose F, editor. Amyotrophic Lateral Sclerosis. New York: Demos, 1990: 33–38. 39.Google Scholar
  28. 28.
    Committee on Health Care Issues of the American Neurological Association. Current status of thyrotropin-releasing hormone therapy in amyotrophic lateral sclerosis. Ann Neurol 40. 1987; 22: 541–543.CrossRefGoogle Scholar
  29. 29.
    Borasio GD. Amyotrophic lateral sclerosis: lessons in trial design from recent trials. J Neurol Sci 1997;152(Suppl 1):S23–41. S28.Google Scholar
  30. 30.
    Albert SM, Murphy P, Del Bene M, Rowland LP. Patient preferences for treatment in amyotrophic lateral sclerosis (ALS): relationship to outcomes one-year post-diagnosis. Proc Am 42. Acad Neurol 25 April-2 May, no. 28. 1998.Google Scholar
  31. 31.
    Medical Research Council. Aids to the examination of the 43. peripheral nervous system. Memorandum 45. London: HMSO, 1976: 1–2. 44.Google Scholar
  32. 32.
    Norris FH, Calanchini PR, Fallat RJ, Panchari S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology 1974; 24: 721–728.PubMedCrossRefGoogle Scholar
  33. 33.
    Hillel AD, Miller RM, McDonald E, Konikow N, Norris FH. 45. Amyotrophic lateral sclerosis severity scale. In: Tsubaki T, Yase Y, editors. Amyotrophic lateral sclerosis: recent advances in research and treatment. Amsterdam: Excerpta Medica 1988: 247–252. 46.Google Scholar
  34. 34.
    Hillel AD, Miller RM, Yorkston K, McDonald E, Norris FH, Konikow N. Amyotrophic lateral sclerosis severity scale. In: Clifford Rose F, editor. Amyotrophic lateral sclerosis. New 47. York: Demos, 1990: 93–97.Google Scholar
  35. 35.
    Robinson I. Analysing the structure of 23 clinical trials in multiple sclerosis. Neuroepidemiology 1987; 6: 46–76.PubMedCrossRefGoogle Scholar
  36. 36.
    Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. Maryland State Med J 1965; 14: 61–65.Google Scholar
  37. 37.
    Louwerse ES, de Jong JMBV, Kuether G. Critique of assessment methodology in amyotrophic lateral sclerosis. In: Clifford Rose F, editor. Amyotrophic lateral sclerosis. New York: Demos, 1990: 151–179.Google Scholar
  38. 38.
    Wynne A. Is it any good? The evaluation of therapy by participants in a clinical trial. Soc Sci Med 1989; 29: 1289 1297.Google Scholar
  39. 39.
    Caroscio JT, Cohen JA, Zawodniak J, et al. A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis. Neurology 1986; 36: 141–145.PubMedCrossRefGoogle Scholar
  40. 40.
    Brooke MH, Florence JM, Heller SL, et al. Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis. Neurology 1986; 36: 146–151.PubMedCrossRefGoogle Scholar
  41. 41.
    Mitsumoto H, Salgado ED, Negroski D, et al. Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials. Neurology 1986; 36: 152–159.PubMedCrossRefGoogle Scholar
  42. 42.
    Chatterton P. Physiotherapy for the terminally ill. Physiotherapy 1988; 74: 42–46.CrossRefGoogle Scholar
  43. 43.
    Roberts L, Counsell C. Assessment of clinical outcomes in acute stroke trials. Stroke 1998; 29: 986–991.PubMedCrossRefGoogle Scholar
  44. 44.
    Lotz B, Brooks B, Sanjak M, et al. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996; 46: 1244–1249.CrossRefGoogle Scholar
  45. 45.
    Miller RG, Petajan JH, Bryan WW, et al. A placebo-controlled clinical trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 256–260.PubMedCrossRefGoogle Scholar
  46. 46.
    Miller RG, Moore D, Young LA, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996; 47: 1383–1388.PubMedCrossRefGoogle Scholar
  47. 47.
    Borassio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F et al. Effect of recombinant human insulin–like growth factor I in amyotrophic lateral sclerosis. Neurology 1998; 51: 583–586.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2001

Authors and Affiliations

  • T. J. Steiner

There are no affiliations available

Personalised recommendations